Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

Trading innovative ideas for academic bursaries worth R275 000
2015-11-09


The top three individual bursary winners with TATA and UFS representatives. From Left:  Naquita Fernandes, Henrike Prinsloo, Lebohang Motsisi, Stefan Strampe, Dr. Johan van Zyl, Jehan van Vuuren, Sanjeeb Lahiri and Salomien Boshoff.
Photo:  Lize Van Den Berg

Learning from industry experts is essential for students’ development. When that learning eases the financial burden of tuition fees, it is even better. TATA Africa has ensured that students from the University of the Free State (UFS) earn academic currency for displaying leadership and business skills.

Jehan Van Vuuren walked away with R40 000 in his student account, Hendrike Prinsloo earned herself R30 000, Stephan Strampe has R25 000 less to worry about when the 2016 academic year arrives, and seven other students managed to save their parents R20 000 each.

These top 10 Strategic Marketing students from the UFS Department of Business Management and Department of Communication Science took up the challenge of devising strategic concepts to be implemented by the Africa branch of TATA Group companies.

TATA Group is a multinational conglomerate which specialises in a wide range of products and services, such as automobile manufacturing, hotel accommodation, construction, textiles, food and beverages, amongst other enterprises operating under its banner. On 15 October 2015, the company’s Head Office representatives signed a cheque for R275 000 to reward the creative input of our students.

Lesle-Ann George won an academic bursary worth R20 000 for her individual effort, and was also part of one of the best four groups that won R10 000 each. She said the competition was an opportunity of a lifetime. The financial aid will be channeled towards the BCom Marketing Honours degree she intends pursuing next year.

The students’ ideas included market research for TATA motors, the development of a mobile application for the Taj Hotel, as well as innovative student-oriented social media, and guerrilla marketing strategies.

“This collaborative partnership between TATA Africa and UFS has provided the students with an opportunity to learn from key role-players in the industry and, in turn, to gain practical exposure to real-life industry happenings,” said Naquita Fernandes, a Business Management lecturer and the competition’s co-organiser.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept